Sökning: onr:"swepub:oai:DiVA.org:uu-149080" >
Plasma TIMP-1 level...
Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer
-
Frederiksen, C. (författare)
-
Qvortrup, C. (författare)
-
Christensen, I. J. (författare)
-
visa fler...
-
- Glimelius, Bengt (författare)
- Uppsala universitet,Enheten för onkologi
-
- Berglund, Åke (författare)
- Uppsala universitet,Enheten för onkologi
-
Jensen, B. V. (författare)
-
Nielsen, S. E. (författare)
-
Keldsen, N. (författare)
-
Nielsen, H. J. (författare)
-
Brunner, N. (författare)
-
Pfeiffer, P. (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2011
- 2011
- Engelska.
-
Ingår i: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 22:2, s. 369-375
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: The aim was to evaluate the association between plasma tissue inhibitor of metalloproteinase-1 (TIMP-1) and serum carcinoembryonic antigen (CEA) levels and outcome in patients with metastatic colorectal cancer (mCRC) receiving XELOX (combination chemotherapy with capecitabine and oxaliplatin) as first-line treatment. Patients and methods: One hundred and twenty patients were included. Blood samples were collected before treatment and 3 weeks later before the next treatment cycle. Plasma TIMP-1 and serum CEA levels were correlated to treatment outcome. Results: No significant associations between baseline TIMP-1 or CEA levels and best response to treatment or progression-free survival (PFS) could be demonstrated. In contrast, high baseline plasma TIMP-1 levels were associated with poor overall survival (OS), P = 0.008, hazard ratio (HR) = 1.80 [95% confidence interval (CI): 1.17-2.78]. Furthermore, increase in TIMP-1 levels from baseline to immediately before the second cycle of chemotherapy had a significant negative effect on survival (P = 0.03, HR = 1.30, 95% CI: 1.02-1.65) while a decrease in TIMP-1 was significantly associated with a higher objective response rate (P = 0.03). Conclusions: Both high baseline and subsequent increase in TIMP-1 levels were associated with shorter OS in patients with mCRC receiving XELOX as first-line treatment, whereas baseline TIMP-1 levels were not associated with response or PFS following XELOX treatment.
Nyckelord
- biomarkers
- metastatic colorectal cancer
- overall survival
- progression-free survival
- response
- XELOX
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Frederiksen, C.
-
Qvortrup, C.
-
Christensen, I. ...
-
Glimelius, Bengt
-
Berglund, Åke
-
Jensen, B. V.
-
visa fler...
-
Nielsen, S. E.
-
Keldsen, N.
-
Nielsen, H. J.
-
Brunner, N.
-
Pfeiffer, P.
-
visa färre...
- Artiklar i publikationen
-
Annals of Oncolo ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet